Mobia Medical, Inc. Common Stock
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $304.4M
- Price
- $9.14
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.64%
- Volume
- 69.1K
About
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.
Quick stats
Shares outstanding33.3M
Computed float13.4M
Float / shares40.4%
Cash runway (months)4.8
Key info
SectorHealthcare
IndustryMedical - Specialties
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001489993
Websitehttps://www.mobia.com
AI Summary
AI-generated1/10
standardbullishoperations update
Mobia Medical Announces Addition of Paired VNS to Updated AHA Stroke Guidelines
Mobia Medical announced that implantable paired Vagus Nerve Stimulation (VNS) has been recognized in the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery as a treatment option for chronic stroke survivors.
The new guideline supports the use of VNS paired with task-specific training to improve upper-limb function, validating Mobia's Vivistim System as the only FDA-approved solution for this approach.
This inclusion addresses a significant gap in care for the roughly 10 million stroke survivors in the U.S., potentially driving increased adoption of the company's technology.